ABSTRACT
Background Most new SARS-CoV-2 epidemics in France occurred following importation from abroad of emerging viral variants. Currently, the control of such risk of new variant importation is based on the negativity of a screening test (PCR or antigenic) and on an up-to-date vaccine status, such as International Air Transport Association travel pass.
Methods Wastewater of 2 planes arriving in Marseille (France) from Addis-Ababa (Ethiopia) on December 2021 were i) tested by RT-PCR for SARS-CoV2 detection, and variants screening; these tests were carried out between landing and custom clearance, ii)sequenced by MiSeq Illumina.
Antigenic tests and sequencing by NovaSeq were carried out on respiratory samples collected from the 56 passengers of the second flight.
Results SARS-CoV-2 RNA suspected of being from the Omicron BA.1 variant was detected on the aircraft’s wastewater.,
SARS-CoV2 RNA was detected for 11 (20%) passengers and the Omicron BA.1 variant was identified.
Conclusion Our work shows the efficiency of aircraft wastewater testing to detect SARS-CoV-2 cases among travelers and identify the viral genotype. It also highlights the low performance for incoming flights from outside Europe to France of the current filter strategy that combines requirement for a vaccine pass and a negative testing before boarding.
Competing Interest Statement
Lorlane Le Targa is employee of Biosellal society. Bernard La Scola is a scientific consultant for GIS Edem solution.
Funding Statement
This research was funded by the French Government under the Investments for the Future program managed by the Agence Nationale de la Recherche (ANR, French National Agency for Research), reference: Mediterranee Infection 10 IAHU 03.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Since July 2021, according to decree No. 2020 551 of 12 May 2020 on the information systems mentioned in Article 11 of Law No. 2020 546 of 11 May 2020 extending the state of health emergency for people arriving from countries classified at risk if the virus circulates actively, all passengers arriving at Marseille airport are proposed to have a naso-pharyngeal swab for SARS CoV 2 antigenic detection according to a joint initiative of the regional prefecture and the regional health agency. Sampling and antigenic detection were performed by the bataillon des marins pompiers de Marseille. The positive samples collected for diagnostic purposes were reused for retrospective genotyping anonymously. According to French law (loi Jarde), anonymous retrospective studies do not require institutional review board approval nor informed consent. This study was approved by the Ethics Committee of the IHU Mediterranee Infection under the number 2022 013.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
